TL;DR
This paper introduces a novel "Line of Sight" (LoS) strategy for nasal spray administration, which significantly improves drug delivery to target sites within the nasal cavity. By computationally modeling airflow and droplet dynamics in patient-specific nasal geometries, the researchers found that directing the spray towards the ostiomeatal complex (OMC) can enhance drug deposition by an average of 8-fold compared to current standard practices.
What Problem Does This Paper Address?
Topical nasal sprays are widely used for treating sinonasal diseases, but their effectiveness is often hampered by inconsistent and ambiguous usage instructions. This leads to significant variability in drug delivery, with a lack of clear guidance on optimal spray techniques. The complex anatomy of the nasal passages, coupled with factors like mucociliary clearance and inter-individual variations, makes it challenging to ensure precise drug deposition at diseased sites. Existing research has focused on computational modeling of airflow and droplet transport, but there's a critical gap in translating these findings into practical, user-friendly recommendations for improving nasal spray efficacy.
Methods
The study employed a multi-faceted approach combining computational fluid dynamics (CFD) simulations with in vitro experiments.
- CFD Simulations: Patient-specific 3D nasal models were created from CT scans. These models were then used to simulate inspiratory airflow and the transport and deposition of drug-carrying droplets using a finite volume approach. The simulations accounted for droplet size distribution and inertial momentum.
- 3D Printing and In Vitro Experiments: Anatomical replicas of the nasal models were 3D printed. These replicas were used for in vitro spray experiments where mildly radioactive spray was administered.
- Gamma Scintigraphy: This technique was used to quantify the deposition of the radioactive spray within the 3D-printed models, allowing for a direct comparison with the CFD simulation results.
- Novel "Line of Sight" (LoS) Protocol: Based on the CFD findings, a new spray administration strategy was proposed. This protocol involves directing the spray axis to aim directly at the ostiomeatal complex (OMC), which is the primary drainage pathway for the sinuses. This contrasts with the "Current Use" (CU) protocol, which generally involves a more general direction and head tilt.
Datasets
The study utilized de-identified computed tomography (CT) data from three pre-surgery chronic rhinosinusitis (CRS) patients. These CT scans were used to create patient-specific 3D anatomical models of the nasal airways. The study also used commercial nasal spray (Nasacort) for in vitro experiments, with its spray characteristics (droplet size distribution, plume angle) characterized using a SprayVIEW NOSP instrument.
Key Insights and Ideas
- Inertial Momentum is Key: Larger droplets, due to their greater inertial momentum, tend to follow their initial trajectory for longer. This can lead to deposition on the anterior nasal walls if not directed properly.
- Targeting the OMC: The ostiomeatal complex (OMC) is identified as the primary target site for drug delivery to treat sinonasal diseases.
- "Line of Sight" (LoS) Strategy: Directing the spray axis to aim precisely at the OMC, rather than a general direction, significantly enhances drug deposition in the target areas. This strategy leverages the inertial motion of larger droplets to guide them to the intended sites.
- CFD as a Predictive Tool: The study demonstrates the power of CFD simulations in predicting drug deposition patterns and evaluating novel administration strategies before in vivo testing.
- Simple Engineering Can Revolutionize Healthcare: The research highlights how relatively straightforward engineering analysis can lead to significant improvements in everyday healthcare practices, like nasal spray usage.
Key Results
- The proposed "Line of Sight" (LoS) spray usage protocol resulted in an average 8-fold improvement in targeted particulate deposition (TSPD) in the OMC and sinuses compared to the "Current Use" (CU) protocol.
- Subject-specific improvements in TSPD ranged from 1.8-fold to 15.8-fold.
- Even with slight perturbations in the spray direction around the LoS, the improvement in TSPD was still significant, averaging a 3.0-fold increase and demonstrating the robustness of the LoS strategy.
- Statistical analysis (paired t-tests and Wilcoxon signed-rank tests) confirmed the statistically significant improvement in deposition with the LoS protocol across all five airway models tested.
- The CFD predictions showed a strong linear relationship and high correlation (Pearson's correlation of 0.91) with the experimental gamma scintigraphy data, validating the computational models.
Limitations and Future Work
- Limited Sample Size: The study used data from only three patients, resulting in five distinct nasal passage models. A larger sample size, including clinical trials, is needed to confirm these findings and revise clinical protocols.
- In Vitro vs. In Vivo: The study relied on in vitro experiments using 3D-printed replicas. While validated, these models do not fully replicate the dynamic biological environment of a living nasal cavity (e.g., mucociliary clearance, mucus interactions, droplet evaporation).
- Laminar Flow Assumption: The CFD simulations assumed laminar airflow, which may not fully capture all the complex flow dynamics, especially in turbulent regions.
- Spray Property Variations: While the study characterized the spray properties of one commercial product, variations in spray characteristics across different products could influence deposition patterns.
- Future Work: The authors suggest a broader study with more subjects and clinical trials to solidify the LoS protocol. They also propose developing a "LoS scoring system" to quantify individual nasal anatomy and guide personalized spray instructions. The findings are also highlighted as relevant for the development of intra-nasal vaccines, particularly in the context of COVID-19.
Summary updated